Tyra Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA) announced its participation in key investor conferences on November 14 and 15-17, 2022. CEO Todd Harris will engage in fireside chats at both events, aiming to showcase the company's innovations in precision oncology. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will feature a chat available on demand, while the Jefferies London Healthcare Conference will include a live chat on November 15 at 10:50 am ET. Webcasts of these discussions will be accessible on the TYRA Investor section.

CARLSBAD, Calif., Nov. 10, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November:

H.C. Wainwright 3^rd Annual Precision Oncology Virtual Conference, November 14, 2022

• Todd Harris, CEO of TYRA, will participate in a fireside chat with the banking equity analyst, available on demand to registered conference attendees.

Jefferies London Healthcare Conference, November 15-17, 2022

• Mr. Harris will participate in a fireside chat with the banking equity analyst on Tuesday, November 15^th, at 10:50 am ET (3:50 pm GMT).

Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Leveraging SNÅP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers. TYRA-300 is an FGFR3 selective inhibitor for oncology. TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:
Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-301675045.html

SOURCE Tyra Biosciences

FAQ

What are the dates of the upcoming conferences for Tyra Biosciences?

Tyra Biosciences will participate in the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, 2022, and the Jefferies London Healthcare Conference from November 15 to 17, 2022.

Who is presenting on behalf of Tyra Biosciences at these conferences?

CEO Todd Harris will represent Tyra Biosciences and participate in fireside chats at both conferences.

What time will Tyra's fireside chat occur at the Jefferies London Healthcare Conference?

The fireside chat at the Jefferies London Healthcare Conference will take place on November 15 at 10:50 am ET (3:50 pm GMT).

Where can I watch the webcasts from Tyra's conference presentations?

The webcasts of Tyra Biosciences' fireside chats will be available on the For Investors page of their website.